TORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, provides clarification on how registered shareholders or duly appointed proxyholders who plan to attend the Company's virtual Annual General and Special Meeting ("Meeting") at 4:30pm EDT today can cast their vote at the Meeting.

Only registered shareholders of record as of the close of business on August 21, 2020, the record date for the Meeting, or their duly appointed proxyholders, will be entitled to vote at the virtual Meeting. Shareholders of record and duly appointed proxyholders must, prior to the start of the Meeting (1) access the Meeting by connecting through the link set out below, and (2) connect via phone using the dial-in number set out below in order to be able to vote their shares at the Meeting.

Note: If a registered shareholder has voted their shares online, they do not need to vote them again. The opportunity to vote at the Meeting is only if they wish to change the way their shares are voted.

Access via the following link:

https://78449.themediaframe.com/dataconf/productusers/ther/mediaframe/40318/indexl.html

AND

Dial-in using either of these phone numbers: 1-877-407-8037 (toll-free) or (201) 689-8037 (toll)

In terms of the voting procedure, all confirmed registered shareholders and duly appointed proxyholders in attendance via live webcast and teleconference will be able to vote their shares by pressing *1 on their telephones on each of the matters tabled at the Meeting, as will be further explained at the start of the Meeting.

Each registered shareholder or duly appointed proxyholder is entitled to one vote for each common share held as of the close of business on the record date of August 21, 2020.

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses.

Additional information is available at www.theralase.com and www.sedar.com

Forward Looking Statement:

This news release contains "forward-looking statements" which reflect the current expectations of Company's management for future growth, results of operations, performance, business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions; including, with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its commercialization plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)
416-699-LASE (5273)
www.theralase.com

Kristina Hachey
Chief Financial Officer
khachey@theralase.com
416-699-LASE (5273) x 224

SOURCE: Theralase® Technologies Inc.

ReleaseID: 607583

Amazon to begin online sales of Else Soy free Plant-Based Toddler Nutrition in the U.S.

VANCOUVER, BC / ACCESSWIRE / September 24, 2020 / ELSE NUTRITION HOLDINGS INC. (TSXV:BABY)(OTCQX:BABYF)(FSE:0YL) ("Else" or the "Company"), is pleased to announce that its novel, first of its kind plant-based soy free Complete & clean label Nutrition for Toddlers is now available for U.S customers via Amazon.com.

Else is expanding into the world's largest online retailer as consumers continue to eat more meals at home and increasingly rely on grocery delivery services, during the COVID-19 pandemic. Amazon saw online grocery sales triple year-over-year during the second quarter of 2020, as more customers continue to get their groceries delivered rather than going to a physical store.

Selling direct to consumers through online channels, is a major pillar of Else's global go-to-market strategy. Furthermore, the Company's Amazon store will provide a convenient alternative for parents who prefer shopping online.

In addition to its own e-store and the new the Amazon.com store, the Company is aggressively pursuing new channels to bring its novel products to natural food and grocery store aisles and store shelves across the United States. Grocers are eager to satisfy consumer's growing demand for natural, clean, non-dairy and healthy alternative product offerings in the Company's product category. This is further amplified given the massive growth and demand they are currently experiencing as a result of stay at home orders and restaurant closures.

As a result of both a consumer demand – plant-based products continue to significantly outpace overall food sales in the U.S., fueling a significant growth opportunity for retailers.

"We're thrilled to offer Else Nutrition's products US nation wide on Amazon.com," said Mrs. Hamutal Yitzhak, CEO and Co-Founder of Else. "With the launch of our plant-based Toddler complete nutrition, we've been getting many requests from customers who want to purchase our product on Amazon.com. This is a tremendous convenience and accessibility boost using the world's largest e-commerce platform – as we continue our singular focus to bring novel, plant-based, clean nutrition to families," she added.

Else Nutrition's Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is now available on Amazon.com as both single (for US$36) and 4-pack (for US$136).

Canadian consumers can order Else's products at www.elsenutrition.com.

To visit Else's Amazon please see: https://www.amazon.com/dp/B08FM4NRMR/ref=cm_sw_r_wa_api_fab_ZBGAFb01N25NV

Else is pleased to announce that as of September 14, 2020, it retained Winning Media LLC ("Winning Media") for digital marketing and advertising services. Winning Media will be engaged on a month to month term and will be compensated a total of USD$75,000 for its current scope of services. Neither Winning Media nor Else currently own securities in each other. The engagement is subject to approval from the TSX Venture Exchange.

About Else Nutrition Holdings Inc.

Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the "2017 Best Health and Diet Solutions" award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QX board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else's Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children's Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children's Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.

For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.

Media Contact:

Covet Consumer Business Unit
Gianna Totaro
elsenutrition@powerdigitalmarketing.com
P: 1-301-875-6574

Ms. Hamutal Yitzhak, CEO, Co-Founder & Director
ELSE Nutrition Holdings Inc.
E: hamutaly@elsenutrition.com
P: +972(0)3-6445095

Mr. Sokhie Puar, Director
ELSE Nutrition Holdings Inc.
E: sokhiep@elsenutrition.com
P: 604-603-7787

TSX Venture Exchange

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Caution Regarding Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements" within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "will", "expect" or similar expressions. Forward-looking statements in this press release include statements with respect to the anticipated dates for filing the Company's financial disclosure documents. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management's perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others, the expectation that listing on the FSE will create additional liquidity and attract additional investors in the European market. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management's expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Else Nutrition Holdings

ReleaseID: 607528

TORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today that McGill University Health Centre ("MUHC") has re-commenced new patient enrollment and treatment in the Company's Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") clinical study ("Study II").

Study II has enrolled and treated 12 patients to date. Out of the 7 patients that are eligible to receive the second treatment, 5 have been treated and 2 are pending. 2 out of the last 5 patients treated for the second time have been treated with the optimized Study II treatment, which will also be the case for the 2 patients that are pending their second treatment.

Efficacy to date at the 90 day assessment includes:

3 out of 12 patients (25%) have demonstrated a Complete Response ("CR") (Negative cystoscopy and negative (including atypical) urine cytology
3 out of 12 patients (25%) have demonstrated a Partial Response ("PR") (2 patients with negative cystoscopy and positive urine cytology and 1 patient with positive cystoscopy and negative urine cytology), with 2 of these patients having received second treatment.

The Company is in advanced discussions with the US based Trial Management Organization to potentially launch 5 clinical study sites in the United States in 4Q2020, subject to the US economy successfully recovering from the COVID-19 pandemic. If launched in 4Q2020, the Company would expect Study II patient enrollment and treatment in 1Q2021.

Theralase® recently submitted an application to the Food and Drug Administration ("FDA") for Fast Track Approval ("FTA"). The application was denied by the FDA, citing certain improvements required to the application. Theralase has revised the FTA application and has resubmitted it to the FDA. Subject to successful FDA approval of the FTA application, Theralase should be in a position to receive FDA FTA approval in 4Q2020.

Shawn Shirazi, Ph.D., Chief Executive Officer of Theralase stated, "Theralase is pleased that all four Canadian clinical study sites are open for new patient enrollment and we are gearing up to launch 5 additional clinical study sites in the US. We are now able to focus on achieving our interim milestone of treating 20 to 25 patients that could support a Breakthrough Designation application to the FDA. The clinical data collected on the first twelve patients treated shows a favorable clinical response after a single PDT treatment, which the Company expects will improve due to the implemented Study II treatment optimization."

About Study II

Study II utilizes the Therapeutic Dose (0.70 mg/cm2) of TLD-1433 and is focused on the enrollment and treatment of approximately 100 Bacillus Calmete Guérin ("BCG")-Unresponsive NMIBC patients presenting with Carcinoma In-Situ ("CIS") in up to 20 clinical study sites located in Canada and the US.

Study II has a:

Primary endpoint of efficacy (defined by CR at any point in time
Secondary endpoint of duration of CR at 360 days post-initial CR (approximately 450 days post initial Study treatment, assuming CR is achieved at the 90 day assessment)
Tertiary endpoint of safety measured by incidence and severity of Adverse Events ("AEs") grade 4 or higher that do not resolve within 450 days post-initial treatment

The FDA, in its 2018 guidance to industry has stated that, "For single-arm trials of patients with BCG-unresponsive disease, the FDA defines a CR as at least one of the following:

Negative cystoscopy and negative (including atypical) urine cytology
Positive cystoscopy with biopsy-proven benign or low-grade NMIBC and negative cytology
For intravesical therapies without systemic toxicity, the FDA includes, in the definition of a CR, negative cystoscopy with malignant urine cytology, if cancer is found in the upper tract or prostatic urethra and random bladder biopsies are negative.

Intravesical instillation does not deliver the investigational drug to the upper tract or prostatic urethra; therefore, the development of disease in these areas cannot be attributed to a lack of activity of the investigational drug. Thus, sponsors can consider patients with new malignant lesions of the upper tract or prostatic urethra, who have received intravesical therapy to have achieved a CR in the primary analysis; however, sponsors should record these lesions and conduct sensitivity analyses in which these patients are not considered to have achieved a CR."1

About Theralase® Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com

Forward Looking Statement:

This news release contains "forward-looking statements" which reflect the current expectations of Company's management for future growth, results of operations, performance, business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions; including, with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its commercialization plans. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273)
416-699-LASE (5273)
www.theralase.com

Kristina Hachey
Chief Financial Officer
khachey@theralase.com
416-699-LASE (5273) x 224

1 "BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment – Guidance for Industry" Dated: February 2018

SOURCE: Theralase® Technologies Inc.

ReleaseID: 607534

KATY, TX / ACCESSWIRE / September 24, 2020 / Neutra Corporation (OTC PINK:NTRR) subsidiary VIVIS will be entering two new lines of business – equipment leasing and CBD production consulting – in a move intended to generate additional revenue streams. The decision marks the latest accomplishment in a year of tremendous progress for Neutra and VIVIS.

"This is a natural progression for us," said Neutra CEO Sydney Jim. "We've developed a great deal of expertise and have attracted positive attention in the market for the quality of our products and our business success. Other companies now want to follow in our footsteps. We're going to put that to use in developing a new source of revenue."

VIVIS plans to offer consulting services to up-and-coming companies about how to set up and run a CBD production facility. Neutra and VIVIS have successfully opened two such plants in 2020 alone in suburbs outside of Houston. The Sugar Land site opened in the spring, while the Katy facility came on line just recently. Each plant is now producing VIVIS' lab-tested, hemp-based CBD products, such as lotions, salves, etc. The Katy site also helped VIVIS expand its product line with tinctures and gummies.

VIVIS additionally intends to lease CBD production equipment to companies it is providing consulting services to or as a standalone service for companies wanting to start their own lines.

To learn more about these and other VIVIS hemp-based CBD products, visit the company's website at http://viviscbd.com.

About Neutra Corp.

Neutra Corp. (NTRR) is an early-stage research and development company with a focus on bringing modern healthy living solutions to a multibillion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture-one where in which consumers are demanding access to products that promote health and stave off potential health dangers. One of the nutraceutical sub-markets is the new thriving hemp-based CBD market, in which the Company intends to participate. For more information, visit the Company's website at http://www.NeutraInc.com.

NOTICE REGARDING FORWARD LOOKING STATEMENT

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

Neutra Contact:

Sydney Jim
888-433-4033
info@neutrainc.com

SOURCE: Neutra Corp

ReleaseID: 607454

KERRVILLE, TX / ACCESSWIRE / September 24, 2020 / Turner Valley Oil and Gas, Inc. (the "Company") ("Turner") (OTC PINK:TVOG), now doing business as Turner Venture Group, Inc., is pleased to announce it has reached another milestone after settling significant debts outstanding and has completed requirements for OTC Markets filings by submitting each of its past financial statements, disclosures and legal opinion. Turner is pleased to say that it has now obtained Pink Current Information completing Phase 1.

As per the OTC Markets, to qualify for Pink Current Information, a non-reporting Pink company must subscribe to the OTC Disclosure & News service and publish current information pursuant to OTC Markets' Pink Basic Disclosure Guidelines. All current information will be made publicly available on www.otcmarkets.com. More information on each of these steps is available as noted below:

Companies will be processed for Current Information once all required documentation has been submitted:
Financial Statements: Two most recent Annual reports and any subsequent Quarterly Report
Disclosure Statement: Most recent Annual and any subsequent Quarterly Reports
Attorney Letter covering all relevant information for non-audited companies
The Company Profile has been verified through OTCIQ

https://www.otcmarkets.com/corporate-services/information-for-pink-companies

The Company is now operating as a Venture Holding Company that acquires equity interests in innovative products and companies within the health, wellness, sanitation, infrastructure and critical supply chain segments.

The Company's first acquisition, expected to close soon, is a product development company with proprietary CBD hand sanitizer formulas. Additionally, major social influencer partners and corporate distribution contracts are under negotiation to expand product distribution channels. Completion of these contracts are expected to be announced in the near future.

After completing the $25,000.00 seed round previously mentioned the Company has advanced the next round of private placements for $100,000.00 to support our growth strategy and fund additional acquisitions. The Company is pleased to announce it has already received commitments for $65,300.00 from the second round. Shareholders interested should contact the Company for more information.

"It is with great excitement that we have completed Phase 1, finishing the critical steps of settling debts, retiring shares and bringing to compliance disclosure of adequate current information and preparing to finish audits as part of our Phase 2 acquisitions and Form 10 filing," CEO James B. Smith stated.

Please refer to most recent website announcements for more information:

https://tvoginc.com/2020/06/turner-announces-corporate-updates-and-advancement-plan/

https://tvoginc.com/2020/07/turner-venture-group-announces-settlement-of-convertible-debts/

https://tvoginc.com/2020/08/turner-venture-group-announces-completion-of-otc-filings-internal-review/

https://tvoginc.com/2020/09/turner-venture-group-announces-settlement-of-former-management-debts/

About Turner Valley Oil and Gas, Inc.

Turner (OTC:TVOG) is a Venture Holding Company that acquires equity interests in innovative products and companies within the health, wellness, sanitation, infrastructure and supply chain technology segments.

Disclosures

Certain statements in this press release are forward-looking and involve a number of risks and uncertainties. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.

Key Links:

OTCMarkets Profile: http://www.otcmarkets.com/stock/TVOG/profile
Disclaimer: https://TVOGinc.com/contactus/disclaimer/
Corporate Website: http://TVOGInc.com
Twitter: http://twitter.com/tvoginc

Contacts:

James B. Smith, CEO, Chairman
Turner Venture Group, Inc.
Address: 317 Sidney Baker South Suite 400-264
Kerrville, TX 78028
Phone: 1-281-826-4289
Email: TurnerVentureGroupInc@gmail.com

SOURCE: Turner Valley Oil and Gas, Inc.

ReleaseID: 607628

There has been a noticeable expansion in the use of yogurt powder owing to rapid increase in the number of health conscious population and need for maintaining proper digestive health.

DUBAI, UAE / ACCESSWIRE / September 24, 2020 / The yogurt powder market hit a value of US$ 200 million in 2019. On the basis of region, North America and Europe holds the largest revenue share. Middle East and Africa is likely to witness potential growth in this market through 2029. Though COVID-19 might have reduced the consumption due to lesser transportation yet need for quality food and inclination towards healthier lifestyle will remain the same, helping the industry revive soon.

"Investment is seen largely in marketing of attractive packaging solutions. Leading players are now collaborating with product manufacturers for a better insight into the scenario and to strengthen their regional market scenario. Need for skimmed yogurt powder in bakeries and household segments will drive the market at a considerable pace," states the FMI Analyst.

Request a report sample to gain comprehensive market insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-7871

Yogurt Powder Market – Important Takeaways

North America and Europe holds the largest revenue share while Middle East region is set to witness better growth.
Leading players are working on marketing, higher compatibility and innovation of products to accelerate market growth.
Global yogurt powder market will register a CAGR value of 7.5% through the forecast period (2029-2029).
Product wise, skimmed yogurt powder will present better investment opportunities as the market is expected to expand.

Yogurt Powder Market – Driving Factors

Innumerable use of yogurt powder in food, bakery, beverages, household, cosmetic and personal car is driving the market.
Visible expanding preference for diet conscious meals and addition of probiotics in diets will help the market witness steady growth.
There is an increasing demand for skimmed yogurt powder in North America and Europe due to rising number of health conscious population.
Owing to rising income, shifting life-style and investments by international companies, competitive structure will be shaped.

For any Queries Linked with the Report, Ask an Analyst@ https://www.futuremarketinsights.com/ask-question/rep-gb-7871

Yogurt Powder Market – Key Restraints

Entry of new players can be at stake due to higher cost competition.
Poor product innovation is affecting the market growth negatively.

Expected Impact on Market by Coronavirus Outbreak

Falling in the food and beverage industry, yogurt powder market is likely to revive soon because people are shifting to a better and healthier lifestyle. Manufacturing and production of raw materials required is easily available but due to slower trade process on account of social distancing, market can face pressure too. Though food retail and manufacturers might experience loss yet the demand is only going to increase due to the benefit it provides.

Competitive Landscape

Major players in the market include Glanbia Plc, Epi Ingredients, Ace International LLP, Almil AG and Kerry Inc., All of these leading players work on building collaborations with major manufacturers to magnify their production capacity.

Major participants rely on investing into promoting products and unique packaging solutions to expand the market and in developing non-fat yogurt. R&D is investing in expanding product portfolio for better margin.

Get full Report Now@ https://www.futuremarketinsights.com/checkout/7871

More on the report

FMI's analysis presents segmentation on the basis of applications (food, beverage, confectionary, cosmetic, household etc.), nature (organic, conventional), flavours (mango, vanilla, banana etc.) type (skimmed, semi-skimmed, whole yogurt), on the basis of distribution channel and region (North America, Europe, Asia, Middle-East, Africa and Oceania)

Explore Wide-ranging Coverage of FMI's Food and Beverage Landscape

Protein Ingredients Market FMI's analysis gives an insight into key market trends, strategies, regional players and various segments on the basis of form, type, application and region.

White Charcoal Powder Market Find insights into global market scenario and segmentation on the basis of ingredients, application, source and region.

Spirulina Powder Market FMI's report highlights parent market trends and strategies in the market with segments and dynamics through the forecast period (2016-2026).

About FMI

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact

Mr. Abhishek Budholiya
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com

Report: https://www.futuremarketinsights.com/reports/yogurt-powder-market
Press Release Source: https://www.futuremarketinsights.com/press-release/yogurt-powder-market

SOURCE: Future Market Insights

ReleaseID: 607647

Bringing more than a decade of corporate fundraising and higher education expertise, Gray will serve on the Foundation's Trustee Board

CHANTILLY, VA / ACCESSWIRE / September 24, 2020 / CORT, a Berkshire Hathaway Company, announced today that Terri Gray, national higher education sales manager, was selected as a 2021 Foundation Trustee for the Association of College and University Housing Officers-International (ACUHO-I) Foundation, the only organization that raises money for the Association to fund large-scale educational programs, research initiatives and practical innovations for campus housing and residence life professionals around the world. Gray, who will serve as Vice Chair of Annual Programs on the Trustee Board, begins her term on January 1, 2021.

Gray brings more than 10 years of fundraising experience to the board since first joining the Foundation in 2005, and she will work with other board members to advance the Association's Strategic Plan by providing association members with education, knowledge resources, community, influential leadership and advocacy.

"I am truly honored to accept this role and join the Trustee Board for the ACUHO-I Foundation, an organization that I have passionately supported since the start of my career in higher education," Gray said. "Over the years, I have seen the Foundation educate and engage with a number of corporate partners – my current employer included – and I am excited for the opportunity to contribute my expertise and help further raise awareness of the Foundation's educational opportunities, annual events and ways our members can engage with other professionals in the industry."

Gray currently serves as the national higher education sales manager for CORT. Since joining the company in 2012, she has served in this role for the past eight years, directing national efforts to develop and promote annual growth in the higher education market while also serving as an advocate to colleges and universities. At the start of her career, Gray spent five years as assistant director of housing business operations at California State Polytechnic University, Pomona, followed by a combined 10 years in marketing positions at various public safety and engineering companies before joining the CORT team. She has been part of the ACUHO-I Foundation since 2005, where she has established herself as an individual Major Donor, served as a member of the Annual Programs and Corporate Outreach and Giving Committees and supported the Foundation at various events, including the ACUHO-I Conference and Expo (ACE), Southeastern Association of Housing Officers (SEAHO) and the Foundation's fall Conference Series.

"We are delighted about Terri's appointment to the ACUHO-I Foundation Board of Trustees," said Scott Boden, director of development, ACUHO-I Foundation. "Terri has been a dedicated volunteer for so many years and has always demonstrated a commitment to powering the profession of campus housing through this work. We will learn a great deal from her leadership and I'm excited to begin our work together."

For more information on the ACUHO-I Foundation, visit https://www.acuho-i.org/foundation. To learn more about CORT, visit www.cort.com, or follow the company on Twitter, Facebook, LinkedIn and Instagram.

About CORT

CORT, a part of Warren Buffett's Berkshire Hathaway, is the nation's leading provider of transition services, including furniture rental for home and office, event furnishings, destination services, apartment locating, touring and other services. With more than 100 offices, showrooms and clearance centers across the United States, operations in the United Kingdom and partners in more than 80 countries around the world, no other furniture rental company can match CORT's breadth of services and companywide commitment to making a house a home, an office a great place to work and an event a memorable celebration. For more information, please visit www.cort.com.

About ACUHO-I Foundation

The ACUHO-I Foundation raises money to fund large-scale educational programs, research initiatives and practice innovations for campus housing and residence life professionals around the world. As a 501(c)3 nonprofit, the Foundation receives donations from individuals and corporate partners to help advance the ACUHO-I mission, empower those working in campus housing and the residence life profession and engage the broader higher education community.

Media Contact:

Melody Goforth, on behalf of CORT
melody@largemouthpr.com
919.459.6482

SOURCE: CORT

ReleaseID: 607662

LOS ANGELES, CA / ACCESSWIRE / September 24, 2020 / As COVID-19 infections continue nationwide, the key to further slowing the spread is to ask those infected to self-isolate and to identify the people in their circle of contacts who may have been exposed to the virus. This proven public health process, called contact tracing, is successfully used in every outbreak of highly infectious diseases from tuberculosis to measles.

Contact tracing has become a central pillar of COVID-19 response efforts, as preventing just a single COVID-19 infection has an exponential effect on the chain of transmission, leading to a larger reduction of positive cases over time.

Working in tandem with the efforts of the State of California's COVID-19 response infrastructure, Kaiser Permanente, the nation's leading health care provider and not-for-profit healthcare system, is committing $63 million to support contact tracing in California in order to slow the spread of COVID-19.

One of the hardest parts of reducing infections is that it requires more people to stay home and continue isolating, which is particularly challenging for those who do not have the means to remain completely isolated. Dr. Cynthia Telles, a board member for Kaiser Foundation Health Plan and Hospitals, is acutely aware of the concerns of these communities.

"This new funding initiative will connect people who need to stay home with necessary resources, such as food assistance, housing assistance, child care, pharmacy deliveries, and much more," said Dr. Cynthia Telles. "Particularly in the face of an unprecedented health crisis like COVID-19, it is essential that people know that when they stay home to protect other people in their community, they will have support."

The Centers for Disease Control and Prevention (CDC) notes that contact tracing helps protect people, their families and communities by:

Letting people know they may have been exposed to COVID-19 and should monitor their health for signs and symptoms of COVID-19.
Helping people get tested if they have been exposed to COVID-19.
Asking people to self-isolate if they have COVID-19 or self-quarantine if they are a close contact of someone with the disease.

Since joining the Kaiser Permanente board in 2003, and serving as chair of the board's Community Health Committee, Dr. Telles has fought tirelessly for healthcare resources and assets to go directly to the communities that need them most.

"We are proud to be working with Governor Newsom's administration to help slow the spread of COVID-19 and are optimistic about the benefit our contact tracing assistance will have on statewide COVID-19 response efforts," said Dr. Cynthia Telles.

The Kaiser Permanente funding will not only go to connecting Californians with resources necessary to continue self-isolations and quarantining, but they will also directly fund specialized contact tracing teams hired directly from the communities where they will work. As local hires, these teams can provide information and resources to community members with whom they have relationships in their preferred language.

"COVID-19 has disproportionately affected Black and Latino communities," said Dr. Cynthia Telles. "And we are working to ensure that concrete and significant resources are delivered to the communities where there's a real need."

If you have been around someone with COVID-19, the CDC recommends you self-quarantine, staying home and away from others:

Stay home away from others for 14 days (self-quarantine) after your last contact with an infected person and monitor your health.
Stay away especially from people who are at higher risk for getting very sick from COVID-19, such as older adults and people with other medical conditions, if possible.
If you have a fever, cough or other symptoms of COVID-19, ask your care provider if you should get medical care or testing.
If you need support or assistance while in self-quarantine, your county health department and many local community organizations may be able to provide assistance.

For more information, reach out to Andrew Mitchell at Cambridge Global at 404-955-7133.

SOURCE: Kaiser Permanente

ReleaseID: 607663